Over one-third of high-grade serous ovarian cancers have high levels of expression of folate receptor ɑ (FRɑ). You may see where we’re going with this. The phase 3 MIRASOL trial presented in abstract form at ASCO this week reports the FRɑ-targeted agent mirvetuximab soravtansine significantly improved overall survival when compared to physician’s choice next-line chemo among 453 women with platinum-resistant ovarian cancer. | Moore, ASCO 2023
